Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23413328 | 0.84 | LMNA (0.42) | SMN1; SMN2NNMTMKNK1MKNK2CYP3A4 | |
| SCHEMBL6869717 | 0.79 | GABRP (0.56) | SMN1; SMN2CYP3A4TSHRGABRPGABRD | |
| SCHEMBL813450 | 0.76 | PARP1 (0.53) | SMN1; SMN2CYP3A4PARP1TSHRPOLB | |
| SCHEMBL2550519 | 0.75 | PARP1 (0.55) | SMN1; SMN2NNMTCYP3A4PARP1TSHR | |
| SCHEMBL2087730 | 0.74 | FBP1 (0.38) | SMN1; SMN2NNMTIKBKBMAPTRECQL | |
| SCHEMBL29526524 | 0.74 | LMNA (0.39) | SMN1; SMN2NNMTMKNK1MKNK2CYP3A4 | |
| SCHEMBL9506862 | 0.74 | LCK (0.45) | SMN1; SMN2NNMTMKNK1MKNK2CYP3A4 | |
| SCHEMBL890399 | 0.72 | CYP3A4 (0.44) | SMN1; SMN2NNMTCYP3A4PARP1TSHR | |
| SCHEMBL1807992 | 0.72 | KDM4E (0.46) | SMN1; SMN2NNMTCYP3A4PARP1TSHR | |
| SCHEMBL1179736 | 0.72 | POLB (0.50) | SMN1; SMN2CYP3A4PARP1TSHRIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163778-B2 | Pyridines as FBPase inhibitors for treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102026978-A | Pyridine compounds | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| EP-2227452-A2 | PYRIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068468-A2 | PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2009-06-04 | — | — | US | disclosed |
| CN-1221551-C | Aminotriazolopyridiine derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | CN | disclosed |
| EP-1347974-B1 | AMINOTRIAZOLOPYRIDIINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2004-11-03 | — | — | EP | disclosed |
| CN-1486314-A | Aminotriazolopyridine derivatives as adenosine receptor ligands | - | 2004-03-31 | — | — | CN | disclosed |
| EP-1347974-A1 | AMINOTRIAZOLOPYRIDIINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6506772-B1 | Pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are the adenosine receptor. | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2002048145-A1 | AMINOTRIAZOLOPYRIDIINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| US-4022799-A | DYEING, PRINTING OF NATURAL AND SYNTHETIC MATERIALS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4001253-A | NAPHTHOLACTAM DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3950347-A | NAPHTHOLACTAM DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | FBP1, PDXK, G6PC1 | SMN1; SMN2 3588/4885NNMT 237/4885MKNK1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.